Strategic Partnerships in Advancing New Approach Methodologies
Charles River is embracing innovation in science and technology to enhance the way we serve our clients and bring novel therapies to patients faster by leveraging progress across three primary focus areas to advance alternative methods in the industry.
WEBINAR: Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening
This webinar showcases how the Retrogenix® platform empowers smarter, earlier decisions across biologic formats. You’ll also learn how this platform, recently accepted into the FDA’s ISTAND Pilot Program, aligns with evolving regulatory support for NAMs and the shift toward reduced animal use.
Watch the Replay
Tools and Platforms
Bit.Bio
Through a strategic partnership with bit.bio, we provide access to a broadening bank of authentic human cells for use in target discovery, validation, and screening services. In drug discovery and safety, bit.bio’s unique ability to generate reprogrammable human cells at scale enables the development of therapies with a higher success rate among patients.
Pathoquest
We’ve expanded our comprehensive portfolio of services to include next-generation sequencing (NGS) services, powerful alternative to animal testing and compliance assistance in the detection of viral contaminants in Biologics, through this partnership.
Pluristyx
This partnership provides broad access to highly characterized and unique stem cell lines, including embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs), as research tools to support the development of novel therapeutics.
Retrogenix®
Rounding out our large molecule and cell therapy capabilities, the proprietary Retrogenix Cell Microarray Technology uncovers high-quality, exploitable drug targets and mechanisms of action as well as screens for potential off-targets to inform lead selection and generates high-quality quality IND-enabling specificity data. *Partnership to acquisition.
Toxys ReproTracker®
Through our partnership with Toxys, Charles River clients gain streamlined access to ReproTracker—a human stem cell-based in vitro assay that complements traditional DART methods. It enables early-phase toxicity screening, animal-free teratogenicity testing, and supports human extrapolation of animal data.
Digital Technology Alternatives
AITIA
This strategic agreement utilizes Logica® in discovery programs for neurodegenerative diseases and oncology, and introduces the possibility of building digital twins of organs and animal models, resulting in workflows where targets and therapeutics are first tested in silico, providing for more refined follow-on animal studies.
Deciphex
In partnership with Deciphex, we’ve accelerated pathology assessments using advanced digital tools for faster data delivery. Through the VICT3R initiative, we’re also pioneering Virtual Control Groups to reduce animal use in toxicology, enhancing scientific rigor and supporting ethical research aligned with the 3Rs.
Fios Genomics
Our longstanding relationship with Fios Genomics gives clients access to bioinformatics data analysis services, including expert analytical support for microarrays, next generation sequencing (NGS), proteomics, metabolomics, epigenetics, and associated metadata that keeps their projects moving forward.
Valo Health
Recognizing the challenges of preclinical drug discovery, we are advancing our in silico opportunities with Logica®, a transformational drug discovery platform with integrated artificial intelligence born from this strategic partnership.